Reference number : GC-2017-Q1-01695, amendment number : , agreement type : G, recipient legal name : Willerth, Stephanie (University of Victoria), recipient country : CA, recipient province : nan, recipient city : British Columbia|Colombie-Britannique, recipient postal code : nan, program name english : Discovery Grants Program - Individual, program name french : Programme de subventions à la découverte - individuelles, program purpose english : Different kind of cells make up the brain and spinal cord. Replicating these complex structures provides us with a significant opportunity to discover how such tissues form in the body. Such engineered neural tissues can be used for applications in pharmacological screening instead of donated human tissues. One popular strategy for tissue engineering uses biomaterial scaffolds to deliver signals that promote stem cells to differentiate into neural tissue. My group works with human induced pluripotent stem cells (hiPSCs), adult cells reprogrammed into a state where they can become any type of cell found in an organism. This property makes them an excellent cell source for tissue engineering. My group identified a number of chemical and physical cues that drive the differentiation of hiPSCs into neural tissue, which serves as a starting point for this research program. However, current methods for engineering neural tissue using hiPSCs require lengthy, labor intensive protocols. The overarching goal of this research program is to engineer functional neural tissues from hiPSCs by developing bioactive scaffolds that present the necessary chemical and physical cues for promoting rapid differentiation that can be translated into bioprinting applications. This research program consists of two different aims for achieving this goal, and the results of this research program will be used to generate neural tissue in a rapid and high throughput manner compared to current methods. 
 
The first aim investigates how to modify the properties of 3D fibrin scaffolds so that they can generate functional neural tissue from hiPSCs. We can manipulate the mechanical properties of these scaffolds using cross-linking agents to increase their stability. We also can enhance their chemical properties by functionalizing them with bioactive cues like peptides that promote neuronal differentiation of hiPSCs. We will then determine the influence of these two types of cues on hiPSC differentiation by using these scaffolds as bioink for 3D printing of functional neural tissues. 
 
The second aim will elucidate how the controlled release of novel chemical cues from microspheres can rapidly differentiate hiPSCs into neurons. These chemical cues include the transcription factor Ascl1 (shown to efficiently produce neurons) functionalized with intracellular protein delivery technology, purmorphamine (shown to enhance motor neuron differentiation), and guggulsterone (shown to enhance dopaminergic neuron differentiation). Currently, no existing drug delivery systems can generate controlled release of these molecules &ndash; all of which promote rapid differentiation of hiPSCs into neural tissue. We will demonstrate how different combinations and concentrations of these drug-releasing microspheres can be used to engineer two different types of neural tissue, which could then be used for drug screening applications., program purpose french : Different kind of cells make up the brain and spinal cord. Replicating these complex structures provides us with a significant opportunity to discover how such tissues form in the body. Such engineered neural tissues can be used for applications in pharmacological screening instead of donated human tissues. One popular strategy for tissue engineering uses biomaterial scaffolds to deliver signals that promote stem cells to differentiate into neural tissue. My group works with human induced pluripotent stem cells (hiPSCs), adult cells reprogrammed into a state where they can become any type of cell found in an organism. This property makes them an excellent cell source for tissue engineering. My group identified a number of chemical and physical cues that drive the differentiation of hiPSCs into neural tissue, which serves as a starting point for this research program. However, current methods for engineering neural tissue using hiPSCs require lengthy, labor intensive protocols. The overarching goal of this research program is to engineer functional neural tissues from hiPSCs by developing bioactive scaffolds that present the necessary chemical and physical cues for promoting rapid differentiation that can be translated into bioprinting applications. This research program consists of two different aims for achieving this goal, and the results of this research program will be used to generate neural tissue in a rapid and high throughput manner compared to current methods. 
 
The first aim investigates how to modify the properties of 3D fibrin scaffolds so that they can generate functional neural tissue from hiPSCs. We can manipulate the mechanical properties of these scaffolds using cross-linking agents to increase their stability. We also can enhance their chemical properties by functionalizing them with bioactive cues like peptides that promote neuronal differentiation of hiPSCs. We will then determine the influence of these two types of cues on hiPSC differentiation by using these scaffolds as bioink for 3D printing of functional neural tissues. 
 
The second aim will elucidate how the controlled release of novel chemical cues from microspheres can rapidly differentiate hiPSCs into neurons. These chemical cues include the transcription factor Ascl1 (shown to efficiently produce neurons) functionalized with intracellular protein delivery technology, purmorphamine (shown to enhance motor neuron differentiation), and guggulsterone (shown to enhance dopaminergic neuron differentiation). Currently, no existing drug delivery systems can generate controlled release of these molecules &ndash; all of which promote rapid differentiation of hiPSCs into neural tissue. We will demonstrate how different combinations and concentrations of these drug-releasing microspheres can be used to engineer two different types of neural tissue, which could then be used for drug screening applications., agreement title english : Engineering neural tissue using pluripotent stem cells, agreement title french : Engineering neural tissue using pluripotent stem cells, agreement number : RGPIN, agreement value : 120000.0, agreement start date : 2017-05-10, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year. (2017-2018 to 2022-2023), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2022-2023), owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada